Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

Study Purpose

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 40 Years - 85 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Age 40 to 85 years, inclusive, at screening initiation. 2. Diagnosis of IPF as defined by ATS/ERS/JRS/ALAT guidelines (Raghu 2018). 3. History of IPF diagnosis within the past 5 years with onset defined as the date of the first recorded diagnosis of IPF by HRCT and/or SLB in the medical history. 4. Interstitial pulmonary fibrosis defined by HRCT scan at Screening, with evidence of ≥10% to <50% parenchymal fibrosis (reticulation) and <25% honeycombing, within the whole lung, as determined by the HRCT central reader. 5. FVCpp value ≥50% and ≤90% at Screening. 6. Diffusing capacity of the lungs for carbon monoxide (DLCO) percent of predicted and corrected by Hb value ≥30% and ≤90% at Screening. 7. Both FVC and DLCO testing must be representative of the IPF underlying disease. 8. Not currently receiving treatment for IPF with approved or unapproved therapy. 9. Male subjects with partners of childbearing potential and female subjects of childbearing potential (including those <1 year postmenopausal) must use double barrier contraception methods during the conduct of the study, and for 3 months after the last dose of study drug. 10. Able to understand and sign a written informed consent form.

Exclusion Criteria:

1. Previous exposure to pamrevlumab. 2. Evidence of significant obstructive lung disease by any of the following criteria:
  • (1) forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio <0.70, or (2) extent of emphysema greater than the extent of fibrosis on HRCT.
3. Female subjects who are pregnant or nursing. 4. Smoking within 3 months of Screening and/or unwilling to avoid smoking throughout the study. 5. Interstitial lung disease other than IPF. 6. The Investigator judges that there has been sustained improvement in the severity of IPF during the 12 months prior to Screening, based on changes in FVC, DLCO, and/or HRCT scans of the chest. 7. History of other types of respiratory diseases including diseases or disorders of the airways, lung parenchyma, pleural space, mediastinum, diaphragm, or chest wall that, in the opinion of the Investigator, would impact the primary protocol endpoint or otherwise preclude the subject's participation in the study. 8. Medical conditions (e.g. MI/stroke within the past 3-6 month) or logistical challenges that in the opinion of the Investigator preclude the subject's adequate participation in the study. 9. Poorly controlled chronic heart failure (NYHA Class 3 or above); clinical diagnosis of cor pulmonale requiring specific treatment; or severe pulmonary arterial hypertension requiring specific treatment that, in the opinion of the Investigator, would preclude the subject's participation in the study. 10. Clinically important abnormal laboratory tests (including serum creatinine ≥1.5 x upper limit of normal [ULN], hemoglobin (Hb) <10 g/dL, white blood cells <3,000/mm3, platelets less than 100,000/mm3, serum total bilirubin >1.5 x ULN, serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 x ULN, or serum alkaline phosphatase ≥2 x ULN. 11. Ongoing acute IPF exacerbation, or suspicion of such process by the Investigator, during Screening or Randomization. 12. High likelihood of lung transplantation (in the opinion of the Investigator) within 6 months after Day 1. 13. Use of any investigational drugs or unapproved therapies, for IPF or not, in the 30 days prior to screening initiation. Or use of approved IPF therapies within 5 half-lives of screening. 14. Daily use of PDE-5 inhibitor drugs [e.g. sildenafil, tadalafil, other]. (Note: Intermittent use of one type for erectile dysfunction or severe pulmonary hypertension is allowed). 15. Any history of malignancy likely to result in significant disability or mortality likely to require significant medical or surgical intervention within the next 2 years. This does not include minor surgical procedures for localized cancer (e.g., basal or squamous cell carcinoma of skin). 16. History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies. 17. Any condition (other than IPF) that is likely to result in the death of the patient within the next year. 18. The Investigator judges that the subject will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, addiction, or any other relevant medical or psychiatric conditions.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03955146
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

FibroGen
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Idiopathic Pulmonary Fibrosis
Additional Details

This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to evaluate the efficacy and safety of pamrevlumab in subjects with idiopathic pulmonary fibrosis (IPF) over a 52 week period. Subjects who are not being treated with approved therapies (e.g. nintedanib and pirfenidone) may be eligible for screening. Examples of reasons subjects may not be treated with approved therapies include:

  • - Intolerant or ineligible to receive therapy, as per the Principal Investigator - Previously received therapy, but discontinued - Subject voluntarily declines to receive approved therapies after being fully informed of the potential benefits/risks Approximately 565 eligible subjects will be randomized at a 3:2 ratio to Arm A or Arm B, respectively: - Arm A: pamrevlumab, 30 mg/kg IV Q3 weeks - Arm B: Matching placebo IV Q3 weeks Study Duration: - Screening period: Up to 6 weeks - Treatment period: 48 weeks - Follow-up period/final assessment: 4 weeks (Week 52) Subjects who complete the 52 week study may be eligible for rollover into a separate study offering open-label, extension treatment with pamrevlumab.
The following assessments will be centralized: pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT).

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Pulmonix, LLC, Greensboro, North Carolina

Status

Recruiting

Address

Pulmonix, LLC

Greensboro, North Carolina, 27403

Site Contact

Jennifer Castillo

jennifer.castillo@pulmonix.com

336-323-5276

The University of Kansas Medical Center, Kansas City, Kansas

Status

Recruiting

Address

The University of Kansas Medical Center

Kansas City, Kansas, 66160

Site Contact

Stephanie Greer

sgreer3@kumc.edu

913-588-4030

Kissimmee, Florida

Status

Recruiting

Address

Pulmonary Disease Specialist, PA d/b/a, PDS Research

Kissimmee, Florida, 34741

Site Contact

Cathy Goodwin, CCRC

cgoodwin@pds-cfsc.com

407-624-4831

Terms of Service

The PFF does not promote or represent that any investigational new drugs mentioned are safe or effective. The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. For a full description of terms please refer to our Terms, Conditions & Privacy.

Back to Top
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >